OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	48
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	47
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	33
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	27
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	22
Learning pharmacometric covariate model structures with symbolic regression networks	21
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	16
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	15
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	14
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	14
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	13
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	13
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	13
Training the next generation of pharmacometric modelers: a multisector perspective	12
Current practices for QSP model assessment: an IQ consortium survey	12
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	11
Informatics for toxicokinetics	11
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	11
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Imputation of missing clock times – application to procalcitonin concentration time course after birth	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	9
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	9

Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	9
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	9
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	8
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	7
Thanks to our Reviewers of 2022!	7
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	7
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	7
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	6
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
JPKPD October Special Issue - Commentary	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Application of machine learning based methods in exposure–response analysis	5
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	5
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	5
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	5
Computing optimal drug dosing with OptiDose: implementation in NONMEM	4
A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics	4
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	4
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	4
Population pharmacokinetic model selection assisted by machine learning	4
Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology	4
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	3
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	3
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	3
Thanks to our reviewers 2021!	3
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	3
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	3
External control arms for rare diseases: building a body of supporting evidence	3

In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	3
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	3
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	3
Should patients skip late doses of medication? A pharmacokinetic perspective	3
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	3
How drug onset rate and duration of action affect drug forgiveness	3
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	3
What should patients do if they miss a dose of medication? A theoretical approach	3
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	3
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	3
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	2
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	2
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	2
Generation and application of avatars in pharmacometric modelling	2
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	2
An industry perspective on current QSP trends in drug development	2
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	2
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	2
Towards a comprehensive assessment of QSP models: what would it take?	2
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	2
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	2
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	2
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	2
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	2
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	2
Correction: External control arms for rare diseases: building a body of supporting evidence	2
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	2
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	2
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	2
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	2
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	2
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	2
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	2
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	2
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	2